1. In Vivo
  2. >>Archive

Contrast Media Manufacturers Lock Up Distribution Channels

Thanks to the continued conversion of customers to non-ionic contrast media, the market for contrast agents exploded to phenomenal heights in the last decade. But with growth slowing, manufacturers are looking to cement their grip on distribution channels through big acquisitions.

Given all the reasons that growth of the contrast media market could have flattened dramatically by now, its rise to about $3.5 billion in worldwide sales last year is remarkable. Once projected to reach $5.5 billion by 1995 (the market was one-tenth that size in 1985), about $1 billion of the 1995 estimate was expected to materialize through the introduction and growth of MRI and ultrasound agents. But only one ultrasound agent, Molecular Biosystems Inc. ’s Albunex, has been approved in the US and sales of MRI agents have grown to only a third of the $900 million projected for 1995.

Driving the growth over the past decade has been the expanded use of low-osmolar, non-ionic contrast agents across a broad...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By David Wild

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.